Zhejiang Benli Technology Past Earnings Performance
Past criteria checks 4/6
Zhejiang Benli Technology's earnings have been declining at an average annual rate of -9.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 4.7% per year. Zhejiang Benli Technology's return on equity is 4.8%, and it has net margins of 8.7%.
Key information
-9.4%
Earnings growth rate
-18.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.7% |
| Return on equity | 4.8% |
| Net Margin | 8.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Zhejiang Benli Technology's (SZSE:301065) Performance Is Even Better Than Its Earnings Suggest
Nov 01
We Think You Should Be Aware Of Some Concerning Factors In Zhejiang Benli Technology's (SZSE:301065) Earnings
May 02Recent updates
Zhejiang Benli Technology's (SZSE:301065) Performance Is Even Better Than Its Earnings Suggest
Nov 01What Zhejiang Benli Technology Co., Ltd.'s (SZSE:301065) 42% Share Price Gain Is Not Telling You
Aug 08Zhejiang Benli Technology (SZSE:301065) Will Pay A Smaller Dividend Than Last Year
Jun 19Lacklustre Performance Is Driving Zhejiang Benli Technology Co., Ltd.'s (SZSE:301065) Low P/E
Jun 07We Think You Should Be Aware Of Some Concerning Factors In Zhejiang Benli Technology's (SZSE:301065) Earnings
May 02Earnings Not Telling The Story For Zhejiang Benli Technology Co., Ltd. (SZSE:301065) After Shares Rise 30%
Mar 08Revenue & Expenses Breakdown
How Zhejiang Benli Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 712 | 62 | 39 | 27 |
| 30 Jun 24 | 734 | 71 | 38 | 28 |
| 31 Mar 24 | 716 | 64 | 40 | 27 |
| 31 Dec 23 | 698 | 60 | 40 | 28 |
| 30 Sep 23 | 686 | 56 | 41 | 29 |
| 30 Jun 23 | 677 | 49 | 39 | 29 |
| 31 Mar 23 | 730 | 56 | 35 | 28 |
| 01 Jan 23 | 759 | 60 | 33 | 27 |
| 30 Sep 22 | 740 | 61 | 32 | 25 |
| 30 Jun 22 | 717 | 61 | 29 | 23 |
| 31 Mar 22 | 662 | 55 | 25 | 21 |
| 01 Jan 22 | 621 | 55 | 27 | 20 |
| 30 Sep 21 | 646 | 71 | 26 | 19 |
| 30 Jun 21 | 653 | 87 | 28 | 18 |
| 31 Mar 21 | 633 | 87 | 30 | 20 |
| 31 Dec 20 | 625 | 92 | 28 | 22 |
| 30 Sep 20 | 605 | 95 | 48 | 34 |
| 31 Dec 19 | 559 | 73 | 27 | 19 |
| 31 Dec 18 | 438 | 45 | 18 | 18 |
| 31 Dec 17 | 337 | 25 | 19 | 12 |
Quality Earnings: 301065 has high quality earnings.
Growing Profit Margin: 301065's current net profit margins (8.7%) are higher than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301065's earnings have declined by 9.4% per year over the past 5 years.
Accelerating Growth: 301065's earnings growth over the past year (11.2%) exceeds its 5-year average (-9.4% per year).
Earnings vs Industry: 301065 earnings growth over the past year (11.2%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 301065's Return on Equity (4.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:25 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Benli Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|